Skip to main content
Equibles
ABUS logo

ABUS · Arbutus Biopharma Corp · Metrics

Track ABUS — free

Use ABUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.27 -0.02 (-0.48%) Q3 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$856.68M
Shares
197.85M
Volume · Oct 28 1.34M Avg daily vol (3M) 4.83M

ABUS metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.32
Market cap
$856.68M

Price action

20 metrics
Price change (1W)
-0.9%
Price change (30D)
-11.7%
Price change (3M)
-2.7%
Price change (6M)
+3.4%
Price change (YTD)
-10.8%
Price change (1Y)
-4.0%
Trailing year
Price change (5Y)
+5.4%
52-week high
$5.22
52-week low
$3.67
Change from 52-week high
-17.8%
Change from 52-week low
+16.9%
Annualized volatility
45.3%
Annualized volatility (3M)
36.9%
Beta
1.1
RSI (14D)
43.1
Price vs SMA 50
-9.7%
Price vs SMA 200
-4.7%
Avg volume (3M)
4.82M
Relative volume
0.3
Average dollar volume
$23.20M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
197.85M

Valuation

12 metrics
P / E (TTM)
5.4
Trailing earnings · reciprocal yield 18.4%
PEG ratio
—
EV / revenue
4.6×
reciprocal yield 22.0%
EV / EBITDA
—
EV / EBIT
5.6×
reciprocal yield 18.0%
P / sales
4.7×
reciprocal yield 21.5%
P / book
3.3
reciprocal yield 30.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
18.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
47.4×
reciprocal yield 2.1%
EV / revenue historical average (5Y)
34.8×
reciprocal yield 2.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-11-21

Profitability

9 metrics
Gross margin
—
Operating margin
82.0%
Trailing 12 months
Net margin
84.2%
Gross profit (TTM)
—
Operating profit (TTM)
$149.00M
Net income (TTM)
$153.05M
Trailing 12 months
Diluted EPS (TTM)
$0.79
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.93
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$0.76
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$0.78
Operating cash flow per diluted share (TTM)
$-0.13
Free cash flow per diluted share (TTM)
$-0.21
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.09
Stock compensation per diluted share (TTM)
$0.03
Book value per share
$0.40

Growth

11 metrics
Revenue growth YoY
-90.6%
Year over year
Net income growth YoY
-303.8%
Revenue (TTM)
$181.72M
Trailing 12 months
EPS growth YoY
-400.0%
Shares change YoY
+2.6%
Year over year · more shares
Revenue CAGR (3Y)
-28.8%
Revenue CAGR (5Y)
+15.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
59.2%
Return on assets
55.9%
Debt / equity
0.0
Current ratio
81.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
81.4
Interest coverage
1,960.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$19.17M
Latest balance sheet
Cash & equivalents
$19.17M
Total assets
$274.02M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$24.62M
Capital expenditures (TTM)
$0
R&D (TTM)
$17.80M
SG&A (TTM)
—
Stock compensation (TTM)
$5.51M
R&D / revenue
9.8%
Stock compensation / revenue
3.0%

Ownership (13F)

9 metrics
13F filers
177
13F filer change QoQ
+7
Institutional ownership
71.3%
Conviction holders (share of 13F filers)
1.1%
Crowding (high-turnover and private-fund holders)
30.0%
Private-fund adviser ownership
28.8%
Active holders' share change QoQ
+5.8%
Holder tenure
15.8
Price vs estimated holder cost
+31.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.7%

Short interest

3 metrics
Short interest
12.4%
Latest settlement · 4.3 days to cover
Days to cover
4.3d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1447028 CUSIP 03879J100 13F (30d) 25 filings 25 filers Visit website Investor relations